搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 24 小时
时间不限
过去 1 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
The Mirror US on MSN
1 小时
Six 'unexpected' signs of potential heart problems that aren't chest pain
Chest pain is often considered the telltale sign of heart trouble - but there are lesser-known symptoms that could indicate ...
9 小时
on MSN
Lesser-known heart attack symptoms that aren't chest pain - and when to see a doctor
Chest pain is often considered the telltale sign of a heart attack, but there are other, lesser-known symptoms that could ...
HealthDay on MSN
9 小时
E. Coli: What It Is, Causes, Symptoms & Treatment
Every year, an estimated 265,000 people in the U.S. suffer from infections caused by a type of bacteria known as Shiga ...
2 小时
Are laxatives for weight loss safe?
Ro shares the skinny on laxatives for weight loss, as well as better ways to lose weight sustainably and safely.
Onlymyhealth
8 小时
Why Resting Heart Rate Matters For Your Health: An Age-By-Age Guide
When these changes occur, symptoms like shortness of breath, dizziness, fainting, or chest pain may be signs of major health ...
health.wusf.usf.edu
1 小时
Homebound seniors living alone often slip through health system’s cracks
There is a large population of older adults with physical problems that prevent them from leaving home. Many have significant ...
openheart.bmj
7 小时
Diagnostic performance of a point-of-care high-sensitivity cardiac troponin I assay among ...
Background A novel handheld point-of-care high-sensitivity cardiac troponin I analyser has recently been introduced to the ...
manilatimes
6 小时
Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the ...
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that ...
Le Lézard
6 小时
Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA ...
Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈